**Description**

**A FORMULATION DISPLAYING ANTI-CARCINOGENIC EFFECT BY SUPPRESSING GLYCOPROTEIN CD44 AND CXC CHEMOKINE RECEPTOR-4 (CXCR4) EXRESSIONS**

**Field of Invention**

The present invention herewith discloses a formulation that displays an anti-carcinogenic effect by suppressing glycoprotein CD44 and CXC chemokine receptor-4 expressions.

**Background of the Related Technology**

At present it is known that the term glycoprotein is a general term used to refer to organic molecules composed of sugar and amino acids. A majority of molecules found in living organisms are glycoproteins in structure. Furthermore proteins and carbohydrates form the glycoproteins. These may play a role in completing many functions in living organisms. On the other hand, certain hormones and certain parts of the immune system involve glycoproteins. Carbohydrates synthesize glycoproteins after they combine with proteins. This synthesized compound then becomes a part of the cell membrane and helps the cell to develop antigenicity. It helps the cells to communicate with each other and to recognize each other. They form the receptors for viruses, bacteria and drugs.

In state of art technology, invention no “WO 2000/010547", with title “New Application Areas for Taxoid Derivatives” and under classification number “A61K 31/335" discloses new areas for using taxoid derivatives. The referred invention is specifically related to a method for preventing abnormal growth observed in cell lines which produce P-glycoprotein, that shows resistance against more than one drug and displays different resistances. Such cells represent the cells of the large intestine. The product within the scope of the referred invention may be used in treatment of large intestine cancer of mammals, including humans.

Again invention no “EP1290028B1", with title “A Gene Homologous in 7p15-21 Chromosome and Encodes P-glycoprotein Resistant to Various Drugs and Related Uses” and under classification number “C07K 14/705" discloses the P-glycoprotein of MDR family that is located on 7p15-21 human chromosome, and is related to the polynucleotide sequences that encode this P-glycoprotein and its related particles. This gene is used in assessment of sensitivity against treatments of the cancer cells, involving their resistance against various drugs and in designing diagnosis and treatment methods regarding resistance to more than one drug in cancer patients. The referred invention is also related to whether a test compound can inhibit resistance against more than one drug.

Again invention no “EP2049519B1", with title “Cyclic Derivatives of Chemokine Receptor Activity as Modulators” and under classification number “C07D 401/12" discloses, in general definition, the chemokine receptor activity modulators that display an unexpected combination of the desired pharmacologic characters. The referred invention also discloses the pharmaceutical compositions that contain these compounds and methods where they are used for treatment and prevention of inflammatory, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases and specifically diabetes, atherosclerosis, Crohn’s disease and multiple sclerosis, and also involves the methods for preparation of these compounds and intermediary products. Metabolites of the active compounds as well as their compositions and their use is also provided here.

To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation that displays an anti-carcinogenic effect by suppressing glycoprotein CD44 and CXC chemokine receptor-4 expressions

**Objective of the Invention**

To overcome the disadvantages experienced in state of art technology;

* One objective of the present invention is for it to display glycoprotein CD44 suppressing capability.
* One other objective of the invention is for it to display CxC chemokine receptor -4 (CXCR4) suppressing capability.

The present invention which is aimed to achieve the above-mentioned advantages, is intended to display an anti-carcinogenic effect by suppressing glycoprotein CD44 and CXC chemokine receptor-4 expressions and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 1-[2-trihydroxy-4-methoxy-3-(3-ethylbüt-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol, 2,3-[2-hydroxy-4-pentahydroxy-3-(3-hexamethylbüt-2-ene-1-yl)phenyl]-3-phenylprop-2-ene-1-one.

Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith.

**Detailed Description of the Invention**

The invention herewith discloses a formulation that displays an anti-carcinogenic effect by suppressing glycoprotein CD44 and CXC chemokine receptor-4 expressions. Referred formulation displays glycoprotein CD44 suppressing capability and CxC chemokine receptor-4 (CXCR4) suppressing capability.

The formulation of the invention presented herewith contains; 1-[2-trihydroxy-4-methoxy-3-(3-ethylbüt-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol, 2,3-[2-hydroxy-4-pentahydroxy-3-(3-hexamethylbüt-2-ene-1-yl)phenyl]-3-phenylprop-2-ene-1-one .

The referred formulation is formed by mixing the above-mentioned components at below percentages by weight;

* 1-99% of 1-[2-trihydroxy-4-methoxy-3-(3-ethylbüt-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol,
* 99-1% of 2,3-[2-hydroxy-4-pentahydroxy-3-(3-hexamethylbüt-2-ene-1-yl)phenyl]-3-phenylprop-2-ene-1-one.

Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof.

The present invention at the same time discloses using the above-referred formulation that displays an anti-carcinogenic effect by suppressing glycoprotein CD44 and CXC chemokine receptor-4 expressions and manufacturing it for such purpose.

**CLAIMS**

1. A formulation intended to display an anti-carcinogenic effect by suppressing glycoprotein CD44 and CXC chemokine receptor-4 expressions, which consists of combining the components selected from the group; 1-[2-trihydroxy-4-methoxy-3-(3-ethylbüt-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol, 2,3-[2-hydroxy-4-pentahydroxy-3-(3-hexamethylbüt-2-ene-1-yl)phenyl]-3-phenylprop-2-ene-1-one in a single form or in combinations thereof.
2. The formulation of Claim 1 which is characterized by containing 1-99% of 1-[2-trihydroxy-4-methoxy-3-(3-ethylbüt-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol by weight.
3. The formulation of Claim 1 which is characterized by containing 99-1% of 2,3-[2-hydroxy-4-pentahydroxy-3-(3-hexamethylbüt-2-ene-1-yl)phenyl]-3-phenylprop-2-ene-1-one by weight.
4. Using the compositions obtained by selecting singly or in combination of components from the group of; 1-[2-trihydroxy-4-methoxy-3-(3-ethylbüt-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol, 2,3-[2-hydroxy-4-pentahydroxy-3-(3-hexamethylbüt-2-ene-1-yl)phenyl]-3-phenylprop-2-ene-1-one from any one as given in Claims 2-3 in manufacturing the formulation intended to display an anti-carcinogenic effect by suppressing glycoprotein CD44 and CXC chemokine receptor-4 expressions.

**SUMMARY**

**A FORMULATION DISPLAYING ANTI-CARCINOGENIC EFFECT BY SUPPRESSING GLYCOPROTEIN CD44 AND CXC CHEMOKINE RECEPTOR-4 (CXCR4) EXRESSIONS**

The invention herewith discloses a formulation that displays an anti-carcinogenic effect by suppressing glycoprotein CD44 and CXC chemokine receptor-4 expressions. Referred formulation displays glycoprotein CD44 suppressing capability and CxC chemokine receptor-4 (CXCR4) suppressing capability.

There are no illustrations.